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Abstract
Aim The aim of this study was to achieve useful insights
into pre-hospital management and procedural performance
for ST-elevation myocardial infarction (STEMI) in the
Netherlands by extrapolating patient characteristics, and
procedural and clinical outcomes of the Dutch patient
cohort from the APPOSITION-III trial.
Methods This is a retrospective analysis from the APPO-
SITION-III trial with respect to the geographical borders
of STEMI management. The APPOSITION-III trial was
a European registry for the use of the STENTYS self-ex-
pandable stent in STEMI patients undergoing primary per-
cutaneous coronary intervention (PPCI). 965 Patients were
enrolled mainly in the Netherlands (n = 420, 43.5 % of the
overall study population), Germany (n = 165) and France
(n = 131). The data from the Dutch cohort were compared
with both the overall study population, and the French and
German cohorts, respectively, as well as the European So-
ciety of Cardiology (ESC) STEMI guidelines.
Results In this trial there was a wide inter-country varia-
tion on symptom-to-balloon time, 165 minutes (120–318)
in the Netherlands, 270 minutes (180–650) in Germany and
360 minutes (120–480) in France, respectively. In general,
a preload of dual antiplatelet therapy (DAPT) combined
with heparin was more often performed in the Dutch and
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French cohort than in the German cohort. DAPT at dis-
charge was high across the whole APPOSITION-III pop-
ulation. No important differences were seen between the
different groups according to the endpoints major adverse
cardiac event and stent thrombosis.
Conclusion In the Dutch cohort of an European multicen-
tre STEMI study (APPOSITION-III trial), the performance
in terms of symptom-to-balloon time, and pre-, peri- and
post-procedural medical treatment is in line with the rec-
ommendations of ESC STEMI guidelines.
Keywords ST-elevation myocardial infarction · Primary
percutaneous coronary intervention
Introduction
Primary percutaneous coronary intervention (PPCI) is the
recommended treatment for ST-elevation myocardial in-
farction (STEMI) according to the most recent European
Society of Cardiology (ESC) guidelines [1]. The ESC
guidelines also make recommendations on appropriateness
(symptom-to-balloon time) and standards (concomitant
medications) for performing PPCI in STEMI patients [1].
To comply with the ESC guidelines, most European
countries have developed national and/or regional net-
works and protocols for PPCI, and perform quality controls
throughout registries. A good example is the Swedish Reg-
ister of Information and Knowledge about Swedish Heart
Intensive Care Admission (RIKS-HIA) [2].
Although the Netherlands was one of the first countries
to perform PPCI [3], experiences with local quality assess-
ments are sparse and there is no Dutch national registry to
assess clinical performance in STEMI treatment [4, 5].
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In order to achieve useful insights into pre-hospital
management and procedural performance for STEMI in
the Netherlands, we extrapolated patient characteristics and
clinical outcomes of the Dutch patient cohort from a large
post-market STEMI study, the APPOSITION-III trial [6],
using the overall population and ESC STEMI guidelines as
reference.
Methods
This is a retrospective analysis from the APPOSITION-III
trial with respect to the geographical borders of STEMI
management. The APPOSITION-III trial was a real-life,
prospective, multicentre, European, one-arm, post-market
registry for the use of the STENTYS self-expandable stent
(STENTYS S.A., Paris, France) in STEMI patients under-
going PPCI. The design and results of the APPOSITION-
III trial have been published in detail previously [6]. This
original manuscript provides information about the inclu-
sion and exclusion criteria and study population flow chart.
Briefly, patients were eligible for inclusion in the study if
they presented with a STEMI caused by a de novo steno-
sis in a native coronary artery. The primary endpoint was
the composite of major adverse cardiac events (MACE)
at one-year post-procedure. A total of 965 patients were
enrolled in 51 hospitals in 14 European countries, mainly
in the Netherlands (n = 420, 43.5 % of the overall study
population, see appendix A for participating centres in the
Netherlands). The remaining patients were enrolled in Ger-
many (n = 165), France (n = 131), and 11 other European
countries. The data from the Dutch cohort were compared
with both the overall study population, and the French and
German cohorts, respectively.
Table 1 Baseline demographics and patient characteristics
Variables Netherlands Germany France p-value Total study population
n = 420 n = 165 n = 131 n = 965
Age (years) 59 ± 12 62 ± 12 59 ± 13 0.083 60 ± 12
Male gender (%) 317 (76) 125 (76) 107 (82) 0.325 743 (77)
Diabetes mellitus (%) 52 (12) 37 (22) 18 (14) 0.008 140 (15)
Hypertension (%) 161 (38) 116 (70) 51 (39) <0.0001 456 (47)
Hypercholesterolaemia (%) 120 (29) 93 (56) 56 (43) <0.0001 404 (42)
Current smoking (%) 240 (57) 83 (50) 79 (60) 0.185 539 (56)
Family history of CAD (%) 199 (47) 46 (28) 38 (29) <0.0001 360 (37)
Previous MI (%) 23 (5.5) 10 (6.1) 2 (1.5) 0.003 46 (4.8)
Previous PCI (%) 28 (6.7) 11 (6.7) 3 (2.3) 0.156 54 (5.6)
Previous CABG (%) 2 (0.5) 0 1 (0.8) 0.577 3 (0.3)
Previous stroke (%) 14 (3.3) 2 (1.2) 6 (4.6) 0.085 25 (2.6)
CAD coronary artery disease, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass graft
Statistical analysis
Continuous variables are presented as mean (± standard
deviation) if normally distributed or median (interquar-
tile range) in case of not-normal distribution. Categorical
variables are presented as frequencies and percentages.
Comparisons between groups were performed using one-
way ANOVA (normal distributed continuous variables),
Kruskal-Wallis (not-normal distributed continuous vari-
ables) or Chi-square test (categorical variables), where
appropriate. The cumulative event rates in the Dutch sub-
group vs. the French and German cohorts were compared
using the log-rank test. A p-value of 0.05 is consid-
ered statistically significant. The statistical analyses were
performed at the Academic Medical Center (Amsterdam,
the Netherlands) using the SPSS software package (ver-
sion 19.0, IBM, Chicago, IL, USA).
Results
Baseline demographics and patient characteristics
The baseline characteristics of the studied groups are sum-
marised in Table 1. There were no differences in mean age
and gender. The cardiovascular risk profile of the Dutch
patients was similar to the overall population, although the
incidence of some of the risk factors was lower compared
with the German cohort.
Peri-procedural characteristics
The general procedural characteristics of the study group
are summarised in Table 2 and Fig. 1. There was a wide
inter-country variation on symptom-to-balloon time in
the APPOSITION-III trial, 165 minutes (120–318) in the
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Table 2 Peri-procedural characteristics
Variable Netherlands Germany France p-value Total study population
n = 420 n = 165 n = 131 n = 965
Symptom onset to balloon time (min) 165 (20–318) 270 (120–615) 360 (180–660) <0.0001 210 (120–480)
TIMI flow culprit vessel pre-procedure <0.0001 –
0 229 (55 %) 92 (56 %) 92 (56 %) – 551 (57 %)
1 54 (13 %) 33 (20 %) 33 (20 %) – 127 (13 %)
2 78 (19 %) 27 (16 %) 27 (16 %) – 162 (17 %)
3 54 (13 %) 13 (8 %) 13 (7.9 %) – 120 (13 %)
TIMI flow culprit vessel post-procedure 0.500 –
0 4 (1.0 %) 4 (2.4 %) 0 – 10 (1 %)
1 1 (0.2 %) 1 (0.6 %) 1 (0.8 %) – 4 (0.40 %)
2 16 (3.8 %) 8 (4.8 %) 5 (3.8 %) – 39 (4 %)
3 397 (95 %) 152 (92 %) 125 (95 %) – 910 (95 %)
TIMI Thrombolysis In Myocardial Infarction
Fig. 1 Time to needle per country
Netherlands, 270 minutes (120–615) in Germany and 360
minutes (180–660) in France, respectively. At initial an-
giography and afterwards, TIMI flow grade 3 in the infarct-
related vessel was comparable for all subgroups.
Medication use
The use of medication pre-hospital (in the ambulance), peri-
procedural and at discharge is shown in Table 3. The Dutch
patients in the APPOSITION-III trial had been preloaded
with acetylsalicylic acid and a P2Y12 inhibitor, in 97 and
93 % of the cases, respectively, and with unfractionated
heparin in 94 % of cases. In general, this treatment regimen
was more often performed in the Netherlands and France
than in Germany. The dual antiplatelet therapy at discharge
was high across the whole APPOSITION-III trial.
Major adverse cardiac events and stent thrombosis
The endpoints MACE and stent thrombosis at 30 days and
one-year follow-up are shown in Table 4. No important dif-
ferences were seen between the different groups according
these endpoints.
Discussion
Despite the fact that reperfusion therapies, in particular
PPCI, have proven substantial effectiveness in clinical tri-
als, worldwide mortality from STEMI outside clinical trials
remains high [7]. In developing countries, both an increas-
ing incidence of risk factors for coronary artery disease
and multiple shortcomings in health policies and therapeu-
tic options can be responsible for a higher mortality [8, 9].
Even within Europe, there is a wide inter-country variabil-
ity in patient characteristics, use of medication and invasive
procedures in STEMI patients [10, 11].
In 2007, for instance, only 40–45 % of European STEMI
patients were treated with PPCI [12]. Especially in the
southern and eastern countries thrombolysis was the pre-
ferred strategy. In northern, western and central Europe,
PPCI was offered to 60–90 % of the STEMI patients [12].
Among all European countries, the Netherlands is expected
to apply best-practice treatment for STEMI, because of the
universal and well-developed healthcare system, the mod-
ern logistics and infrastructures, and the percentage of gross
product invested in healthcare [11, 13]. Historically, the
first study suggesting the advantages of PPCI vs. conven-
tional treatment was indeed performed in the Netherlands in
the early 1990 s [3]. Despite all these assets, it is at present
not possible to assess national performance for STEMI in
the Netherlands because a national registry is not available.
By virtue of the large number of Dutch patients enrolled,
the APPOSITION-III trial offers a good opportunity for
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Table 3 Medication use
Variable Netherlands (%) Germany (%) France (%) p-value Total study population (%)
Pre-procedure (in ambulance)
Acetylsalicylic acid 375/407 (92) 134/165 (81) 118/131 (90) 0.001 838/950 (88)
P2Y12 inhibitor 331/407 (81) 89/165 (54) 108/131 (82) <0.00001 709/950 (75)
Heparin 300/407 (74) 76/165 (46) 66/131 (50) <0.00001 574/950 (60)
Pre- and/or peri-procedure
Acetylsalicylic acid 393/407 (97) 154/165 (93) 125/131 (95) 0.233 897/950 (94)
P2Y12 inhibitor 380/407 (93) 131/165 (79) 124/131 (95) <0.00001 863/950 (91)
Heparin 381/407 (94) 154/165 (93) 89/131 (68) <0.00001 825/950 (87)
Bivalirudin 46/407 (11) 1/165 (1) 3/131 (2) <0.00001 109/950 (12)
Glycoprotein IIb/IIIa inhibitor 147/407 (36) 60/165 (36) 59/131 (45) 0.169 357/950 (38)
Discharge
Acetylsalicylic acid 408/418 (98) 162/165 (98) 128/130 (99) 0.804 941/960 (98)
P2Y12 inhibitor 418/418 (100) 162/165 (98) 130/130 (100) 0.007 954/960 (99)
On DAPT 408/418 (98) 162/165 (98) 128/130 (99) 0.804 939/960 (98)
DAPT dual antiplatelet therapy
Table 4 Major adverse cardiac events and stent thrombosis at 30 days and one-year follow-up
Netherlands Germany France p-value Total study population
n = 420 n = 165 n = 131 n = 965
Events at 30 days Patients Event rate*
(percentage)
Patients Event rate*
(percentage)
Patients Event rate*
(percentage)
– Patients Event rate
(percentage)
MACE 18 4.3 5 3.1 0 – 0.053 34 3.5
Definite/probable ST 17 4.1 5 3.1 0 – 0.066 30 3.1
– Definite ST 15 3.6 3 1.8 0 – 0.061 24 2.5
– Probable ST 2 0.5 2 1.2 0 – 0.350 6 0.6
Events at one-year Patients Event rate*
(percentage)
Patients Event rate*
(percentage)
Patients Event rate*
(percentage)
– Patients Event rate
(percentage)
MACE 32 7.7 21 12.7 12 9.2 0.112 86 8.9
Definite/probable ST 17 4.1 6 3.6 0 – 0.070 33 3.5
– Definite ST 15 3.6 4 2.4 0 – 0.085 27 2.8
– Probable ST 2 0.5 2 1.2 0 – 0.350 6 0.6
*Kaplan-Meier estimates. P-value with log rank test
MACE major adverse cardiac events (defined as the composite of cardiac death, recurrent target-vessel related myocardial infarction and clinical-
ly-driven target lesion revascularization), ST stent thrombosis
studying management of STEMI patients in the Netherlands
[6], at a time when ESC STEMI guidelines had already been
published.
According to the ESC STEMI guidelines, restoring coro-
nary flow in the infarct-related vessel and myocardial tis-
sue reperfusion are of major prognostic importance [1].
A shorter time between the occurrence of ischaemia and
the achievement of reperfusion results in improved myocar-
dial salvage and is associated with better clinical outcomes
[14]. Therefore, in patients presenting with STEMI, phar-
macological and/or mechanical (PCI) reperfusion should
be performed as early as possible [1, 15]. Besides system
delay, symptom duration may accurately reflect the risk not
only of myocardial injury but also long-term mortality as
suggested in a recently published analysis of the HORI-
ZONS-AMI trial [16]. In the APPOSITION-III trial, the
symptom-to-balloon time shows huge differences between
the three studied cohorts and the overall population, with
better performance in the Dutch cohort. These differences
can only partly be explained by a more favourable geogra-
phy (shorter distances) and infrastructure (more highways)
in the Netherlands. Patient awareness of symptoms, fast
response of the emergency services (ambulance) and direct
referral to tertiary PCI-capable hospitals by an ECG trans-
fer system (from ambulance to PCI centre) probably play
a major role [13].
The results of the Dutch cohort of the APPOSITION-III
trial closely resembled those of another, albeit randomised,
STEMI study: the ATLANTIC trial. The ATLANTIC trial
is a multicentre, international, double-arm, double-blind,
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randomised study comparing the uploading of ticagrelor in
the ambulance or at the cathlab in STEMI patients under-
going PPCI [17]. Of the overall 1862 patients, only 7.9 %
came from the Netherlands, while the rest were enrolled
in 12 other European countries. The average symptom-to-
balloon time of the Dutch patients in the APPOSITION-
III trial is 165 minutes, which is almost similar to the 159
minutes in the ATLANTIC trial. First-medical-contact-to-
balloon (FMCTB) time, i. e. the symptom-to-balloon mi-
nus the symptom-to-first-medical-contact time, which is an
index of system delay, was on average 86 minutes in the
ATLANTIC trial. Adams et al. [13] have reported that
this is also comparable with the Dutch situation, at least for
the Great Amsterdam Area. We can speculate that in the
Netherlands real-life STEMI patients already receive the
treatment that is recommended (Class IA) by the ESC for
PPCI standard of performance (FMCTB time <90 min in
80 % of the population), while perhaps in other European
countries this is only achievable in highly selected, strongly
monitored randomised trials. In 2008, the ESC launched the
Stent for Life initiative in order to implement effective PPCI
programs and achieve the same results in all its 47 member
countries across Europe and the Mediterranean basis [11].
Another important factor influencing the restoration of
coronary flow in the infarct-related vessel and related my-
ocardial tissue reperfusion is the routine use of peri-proce-
dural dual antiplatelet (DAPT) (Class 1 A) and antithrom-
botic medication such as unfractionated heparin (Class 1 C).
The analysis of the Dutch subgroup of the Apposition-
III trial shows adequate peri- and post-procedural medi-
cal treatment in 95 %, and 98 % at discharge, respectively.
In particular, the comparison of the preloading strategy
with the German cohort shows important differences in the
APPOSITION-III trial.
Although our retrospective analysis let some differences
emerge in the management of STEMI patients between the
Netherlands and other European countries, this had no sig-
nificant impact on MACE at 30 days and one-year follow-
up. The reason for this lack of effect is uncertain and con-
tradictory with other previous studies, but the explanations
could include a lack of power for MACE, a lack of prospec-
tively registered surrogate outcomes and limited follow-up
at this moment [13]. Most likely the higher occurrence of
specific device-related events (stent thrombosis at 30 days
follow-up in the APPOSITION-III was 3.1 %, while in the
Atlantic was 2.2 %, for instance), as well as the dispropor-
tion in geographical inclusion, and possible selection bias
in the least including countries, could have overshadowed
the effect of earlier reperfusion.
Therefore, although the data from the Dutch cohort from
the APPOSITION-III trial are reassuring, it will be impos-
sible without a national STEMI registry to draw definitive
conclusions on whether treatment performances are ade-
quate for each Dutch patient presenting with STEMI. Both
the National Cardiovascular Data Registry (NCDR) and the
NVVC Connect projects, the first aimed at creating a na-
tional database, and the second at promoting local networks,
will soon shed more light on this subject [18, 19].
Limitations
As already mentioned, the Dutch population described in
this study was retrospectively extracted from a multicen-
tre, albeit all-comers, registry. Due to an inclusion bias
(partly consecutive enrolment) and the limited amount of
patients included, this study cannot be considered a true
epidemiological study, but merely a snapshot with possible
clinical implications. Moreover, the APPOSITION-III trial
was performed in teaching and university hospitals, which
may not entirely represent the reality of any country as
a whole. Time to first medical contact, as well as door-to-
balloon time are important parameters for quality assess-
ment in STEMI. Neither of these data were captured in the
APPOSITION-III study; therefore we can only indirectly
extrapolate the Dutch performance on so-called ‘system de-
lay’.
Conclusion
In the Dutch cohort of an European multicentre STEMI
study (APPOSITION-III trial), the performance in terms of
symptom-to-balloon time, and pre-, peri- and post-procedu-
ral medical treatment matches the recommendation of ESC
STEMI guidelines.
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Appendix A
Participating centres
The Netherlands
● Onze Lieve Vrouwe Gasthuis (Amsterdam): 100 patients
(23.8 %)
● Academic Medical Center (Amsterdam): 100 patients
(23.8 %)
● Albert Schweitzer Hospital (Dordrecht): 89 patients
(21.2 %)
● Erasmus Medical Center (Rotterdam): 63 patients (15 %)
● St. Antonius Hospital (Nieuwegein): 38 patients (9 %)
● VU Medical Center (Amsterdam): 17 patients (4 %)
● Scheper Hospital (Emmen): 8 patients (1.9 %)
● Amphia Hospital (Breda): 5 patients (1.2 %)
Germany
● SLK-Kliniken Heilbronn (Heilbronn)
● Evang. Bethesda Johanniter (Duisburg)
● Klinikum Neuperlach (Munich)
● Elisabeth-Krankenhaus (Essen)
● Klinikum Coburg
● Universitätsklinikum Giessen und Marburg
● Herz- und Diabeteszentrum NRW (Bad Oeynhausen)
● Klinikum der Universität (Munich)
● Klinikum Bogenhausen
France
● CHU La Pitié-Salpêtrière (Paris)
● Clinique Saint-Hilaire (Rouen)
● Institut Hospitalier Jacques Cartier (Massy)
● CHU Henri Mondor (Créteil)
● Centre Cardioloque d’Evecquemont
● Clinique de l’Europe (Amiens)
● La Roseraie (Aubervilliers)
● Centre Hospitalier Victor Dupouy (Argenteuil)
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